Rheumatoid Arthritis: Symptoms, Causes, and How Treatment Works

Rheumatoid arthritis (RA) is a chronic autoimmune disease in which the immune system — instead of defending the body against pathogens — attacks the synovial membrane lining the joints. It affects roughly 0.5-1% of adults worldwide, two to three times more often in women than men, most commonly emerging between ages 30 and 60, though it can appear at any age. That makes RA fundamentally different from the far more commonly discussed joint condition, osteoarthritis — even though the initial symptom can look similar: joint pain and stiffness.

The difference is fundamental. Osteoarthritis is primarily mechanical wear of joint cartilage that accumulates over years with age and load. RA is an inflammatory process driven by your own immune system, which, left untreated, destroys not just cartilage but bone, tendons, and ligaments — and does so far faster than ordinary wear. That difference has direct clinical consequences: time lost before starting RA treatment cannot be made up later. The window for slowing or halting the inflammatory process before irreversible joint damage sets in is limited, which is why early diagnosis is a genuine priority in this disease, not just a formality.

This article is a general medical overview of RA — its mechanism, symptoms, diagnosis, and treatment ladder. If you're specifically interested in the role of omega-3 fatty acids as an add-on to therapy, we cover that separately in our article on omega-3 and rheumatoid arthritis, which discusses a meta-analysis on how supplementation affects disease activity.

In people with a genetic predisposition (strongly linked to the HLA-DRB1 gene complex), the immune system begins producing antibodies against the body's own proteins — most characteristically anti-citrullinated protein antibodies (anti-CCP) and rheumatoid factor (RF). These autoantibodies can appear in the blood years before the first joint symptoms, suggesting the disease process begins well before a patient feels the first pain.

Once the disease becomes active, immune cells infiltrate the joint's synovial membrane, triggering chronic inflammation. The synovium thickens into what's called pannus — inflammatory tissue that progressively destroys cartilage and adjacent bone. This process releases pro-inflammatory cytokines (chiefly TNF-alpha, interleukin-6, and interleukin-1), which drive further inflammation — and these very cytokines are the main targets of the modern biologic drugs discussed later in this article.

Beyond symmetric involvement of the hands and wrists, early RA symptoms often include swollen, tender, "sausage-like" fingers, a general sense of exhaustion and malaise (sometimes preceding joint symptoms by weeks), and in some patients low-grade fever. No single symptom is diagnostic on its own — but the combination, especially in a woman aged 30-60, should prompt a rheumatology referral rather than waiting it out.

RA diagnosis rests on a combination of the clinical picture (number and pattern of affected joints, symptom duration), laboratory tests, and, when needed, imaging. Key blood tests are rheumatoid factor (RF) and anti-CCP antibodies (more specific for RA than RF), plus inflammatory markers — ESR and CRP, which we cover in more depth in our entry on CRP and hsCRP.

An important caveat: some patients with a clinically typical RA presentation test negative for both RF and anti-CCP (so-called seronegative RA) — a negative blood test therefore does not rule out the disease if the clinical picture is convincing. Conversely, a low positive RF without joint symptoms doesn't automatically mean RA, since RF can be elevated in other conditions and in some healthy people, especially older adults. Interpreting results always requires a physician weighing them against the clinical picture.

In practice, RA treatment typically proceeds in stages. The first is conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) — most often methotrexate, sometimes combined with other drugs in this class. If, after an adequate trial (usually 3-6 months), low disease activity or remission isn't achieved, a biologic DMARD (bDMARD) is added — targeting specific pro-inflammatory cytokines precisely, most often a TNF-alpha inhibitor — or a targeted synthetic DMARD (tsDMARD) from the JAK-inhibitor class. This strategy is called "treat-to-target": treatment adjusted step by step toward a clearly defined goal — remission or at least low disease activity — rather than just subjective improvement.

The chronic inflammation characteristic of RA isn't confined to the joints. People with RA have a meaningfully elevated risk of cardiovascular disease — heart attack and stroke — partly comparable to the risk seen in type 2 diabetes, independent of classic risk factors like cholesterol or blood pressure. The mechanism involves chronic inflammation accelerating atherosclerosis. For this reason, effective RA treatment that lowers systemic inflammation is now also viewed as a component of cardiovascular prevention in these patients.

Other possible extra-articular complications include interstitial lung disease, dry eye and dry mouth (sometimes overlapping with Sjögren's syndrome), rheumatoid nodules under the skin, and, less commonly, vasculitis. Regular rheumatology care therefore monitors more than just the joints — one reason self-managing symptoms without diagnosis and medical supervision is particularly risky in this disease.

Drug treatment remains the backbone of RA therapy, but lifestyle has a real, if supporting, effect on disease course. Regular physical activity tailored to the patient's ability — including low-intensity resistance training — helps preserve joint range of motion and muscle strength without increasing disease activity, contrary to older fears that exercise "aggravates" RA. Quitting smoking is one of the few modifiable risk factors with well-documented effects on both the risk of developing RA and the effectiveness of later biologic treatment.

As for supplementation, the best-studied dietary element in the RA context is omega-3 fatty acids — we cover the evidence in detail, including a meta-analysis of randomized clinical trials, in a separate article on omega-3 and rheumatoid arthritis. In short: the evidence points to moderate improvement in subjective symptoms and some inflammatory markers, but omega-3 doesn't replace DMARD or biologic treatment — it's an adjunct, not an alternative.

RA is one of those diseases where time directly affects prognosis — and, at the same time, one where early symptoms are easiest to dismiss, because they resemble ordinary fatigue or "typical" joint aches. If morning stiffness in several joints persists for weeks, it's worth treating as a concrete signal to seek diagnosis rather than waiting for symptoms to resolve on their own — because in RA, unlike many other complaints, waiting has a real cost.